New FDA Reporting Requirement For Oxygen Transfillers

Published in Government Relations on January 07, 2022

DME providers who transfill oxygen appear to now be required to submit reports to the FDA to show how many units of certain drugs, including medical gases (oxygen) they dispensed. Until now, providers who transfilled oxygen were required to simply register with the FDA, but there was no reporting requirement. The new reporting requirement stems from the CARES Act, which modified the Food, Drug, and Cosmetics (FD&C) Act.

In 2022, the first year of the reporting requirements, there will be two reports due, one for 2020 and one for 2021. Reports for calendar year 2020 should be submitted no later than February 15, 2022, and reports for calendar year 2021 should be submitted no later than May 16, 2022. Reports for subsequent calendar years should be submitted no later than February 15 of the following year. Each report submitted must include the listed drug, identified by its National Drug Code (NDC), and be organized by the amount of drug released each month. DME providers reporting on the amount of oxygen they dispensed will need to report quantities for each size of gaseous cylinder or liquid reservoir that was transfilled.

Based on our interpretation of the guidance, the term “transfiller” would include companies that fill liquid and/or gaseous oxygen reservoirs/cylinders/containers, etc.

The full draft guidance from the FDA can be found here: https://www.federalregister.gov/documents/2021/11/01/2021-23722/reporting-amount-of-listed-drugs-and-biological-products-under-section-510j3-of-the-federal-food. An excerpt from that guidance reads: The “FDA is announcing the availability of a draft guidance for industry entitled “Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the FD&C Act.” On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted to aid response efforts and ease the economic impact of the Coronavirus Disease 2019 (COVID-19). In addition, the CARES Act included authorities to enhance FDA's ability to identify, prevent, and mitigate possible drug shortages by, among other things, improving FDA's visibility into drug supply chains. Section 3112(e) of the CARES Act (Pub. L. 116-136) added section 510(j)(3) of the FD&C Act (21 U.S.C. 360(j)(3)) to require that each person (including repackers and relabelers) who registers with FDA under section 510 of the FD&C Act with regard to a drug must report annually to FDA the amount of each listed drug that was manufactured, prepared, propagated, compounded, or processed by such person for commercial distribution.

This draft guidance is intended to assist registrants of drug establishments in submitting to FDA reports on the amount of each listed drug manufactured, prepared, propagated, compounded, or processed for commercial distribution, as required by section 510(j)(3) of the FD&C Act. The draft guidance addresses the content of reports, the timing of reports, and the process for report submission.

This draft guidance describes the process that should be used for reporting by each person who registers with FDA under section 510 of the FD&C Act with regard to a listed drug (including a finished dosage form product, an active pharmaceutical ingredient, and other listed drugs), except for biological products or categories thereof exempted by an order under section 510(j)(3)(B)). The process described in this guidance applies to such reporting with respect to listed drugs, including medical gases…”

The definition of “medical gas” in Section 575 of the FD&C Act includes oxygen, nitrogen, nitrous oxide, carbon dioxide, helium, carbon monoxide, and medical air.

Some helpful links that provide additional information related to this topic are listed below:

Portal that providers will initially register and ultimately submit their reports to the FDA: https://edm.fda.gov/EDMIDPLogin/welcome?response_type=code&client_id=0oa1as7rb2poiYTch297&scope=openid%20profile&state=1097800867_1640719521396&redirect_uri=https%3A%2F%2Fedm.fda.gov%2Foidcclient%2Fedmrp

Draft guidance issued by the FDA: https://www.fda.gov/media/153665/download

CARES Act: https://www.congress.gov/116/bills/hr748/BILLS-116hr748enr.pdf

FD&C Act: https://www.govinfo.gov/content/pkg/COMPS-973/pdf/COMPS-973.pdf


TAGS

  1. general
  2. regulatory

From Our Experts

Senate Dear Colleague Letter on Power Seat Elevation and Standing Systems Begins to Circulate thumbnail Senate Dear Colleague Letter on Power Seat Elevation and Standing Systems Begins to Circulate Please reach out to your representatives to ask them to sign the Dear Colleague letters, which request that CMS advance Medicare coverage for power seat elevation systems and urge them to promptly move forward with the process for power standing systems. U.S. Rehab and VGM Government Relations Attend Congressional Briefing in Washington D.C. thumbnail U.S. Rehab and VGM Government Relations Attend Congressional Briefing in Washington D.C. Wednesday, Sept. 14, was a momentous day of advocating for CRT and other key legislative issues. Greg Packer and Tom Powers spent time in Washington D.C. attending the NCART/NRRTS Virtual Congressional Fly-In and a congressional briefing on power seating and standing systems for power wheelchairs. State Association Spotlight: PAMES and Big Sky AMES thumbnail State Association Spotlight: PAMES and Big Sky AMES We recently chatted with the Executive Director of PAMES and BIG Sky AMES, Barb Stockert, about her and the success of the two state associations that she works with. That's a Wrap... Here is a Recap of 2022's August of Action! thumbnail That's a Wrap... Here is a Recap of 2022's August of Action! The VGM Government Relations team worked hard this August of Action to make sure that they met with as many elected officials as possible while they were back in their home states and districts. Read about their meetings here! Representative Ashley Hinson Visits VGM in Waterloo, IA thumbnail Representative Ashley Hinson Visits VGM in Waterloo, IA On September 7, 2022 VGM hosted Congresswoman Ashley Hinson at our main campus. This was her second time visiting VGM in the past few years, the first being right before the pandemic and so she was able to see the differences in the corporate environment. DME Industry Disaster Cost Survey Open thumbnail DME Industry Disaster Cost Survey Open We need to hear from you! Your participation in the survey is important as we need a robust response from the DME community as we gather intel to make improvements to reimbursement during disasters. Reminder: CMS has Two Open Comment Periods and Needs to Hear From You! thumbnail Reminder: CMS has Two Open Comment Periods and Needs to Hear From You! Be sure to make your voice heard with the two comment periods that CMS currently has open. One is regarding Medicare Advantage Plans (deadline Aug. 31) and the other is regarding why Medicare should cover power seating systems in complex power wheel chairs (deadline Sep. 14). Be sure to speak up today! VGM Government Relations Attends an Event with Rep. Cathy McMorris Rodgers thumbnail VGM Government Relations Attends an Event with Rep. Cathy McMorris Rodgers On Friday, August 19, Representatives from VGM Government Relations, AAHomecare, and Norco met with Representative Cathy McMorris Rodgers to advocate and educate for the DMEPOS industry.